OB-220
Significant Fibrosis
PreclinicalActive
Key Facts
About Ochre Bio
Ochre Bio is a private, preclinical-stage biotech pioneering a data-driven approach to liver disease. The company has built a unique 'Human Discovery Platform' combining extensive human liver datasets, AI-driven causal prediction, and validation in sophisticated human ex vivo models like perfused livers. This integrated strategy, coupled with an in-house RNA therapeutic manufacturing capability, aims to rapidly translate novel targets into clinical candidates, as evidenced by a significant partnership with GSK and a pipeline targeting fibrosis and cirrhosis.
View full company profileTherapeutic Areas
Other Significant Fibrosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Multiple Mechanism Program | Ochre Bio | Discovery |